• 1
    Billingham R, Brent L, Medawar P. Actively acquired tolerance’ of foreign cells. Nature 1953; 172: 603606.
  • 2
    Lakkis FG, Arakelov A, Konieczny BT, Inoue Y. Immunologic ‘ignorance’ of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 2000; 6: 686688.
  • 3
    Kreisel D, Krupnick AS, Gelman AE et al. Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nat Med 2002; 8: 233239.
  • 4
    Kreisel D, Krupnick AS, Balsara KR et al. Mouse vascular endothelium activates CD8+ T lymphocytes in a B7-dependent fashion. J Immunol 2002; 169: 61546161.
  • 5
    Zhou P, Hwang KW, Palucki D et al. Secondary lymphoid organs are important but not absolutely required for allograft responses: Am J Transplant 2003; 3: 259266.
  • 6
    Heeger PS. T-cell allorecognition and transplant rejection: a summary and update. Am J Transplant 2003; 3: 525533.
  • 7
    Lechler RI, Lombardi G, Batchelor JR, Reinsmoen N, Bach FH. The molecular basis of alloreactivity. Immunol Today 1990; 11: 8388.
  • 8
    Gould DS, Auchincloss H Jr. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today 1999; 20: 7782.
  • 9
    Auchincloss H Jr, Lee R, Shea S, Markowitz JS, Grusby MJ, Glimcher LH. The role of ‘indirect’ recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci U S A 1993; 90: 33733377.
  • 10
    Benichou G, Takizawa PA, Olson CA, McMillan M, Sercarz EE. Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. J Exp Med 1992; 175: 305308.
  • 11
    Benichou G, Fedoseyeva E, Lehmann PV et al. Limited T cell response to donor MHC peptides during allograft rejection. Implications for selective immune therapy in transplantation. J Immunol 1994; 153: 938945.
  • 12
    Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol 1999; 162: 352358.
  • 13
    Watschinger B, Gallon L, Carpenter CB, Sayegh MH. Mechanisms of allo-recognition. Recognition by in vivo-primed T cells of specific major histocompatibility complex polymorphisms presented as peptides by responder antigen-presenting cells. Transplantation 1994; 57: 572576.
  • 14
    Valujskikh A, Matesic D, Gilliam A, Anthony D, Haqqi TM, Heeger PS. T cells reactive to a single immunodominant self-restricted allopeptide induce skin graft rejection in mice. J Clin Invest 1998; 101: 13981407.
  • 15
    Yamada A, Chandraker A, Laufer TM, Gerth AJ, Sayegh MH, Auchincloss H Jr. Recipient MHC class II expression is required to achieve long-term survival of murine cardiac allografts after costimulatory blockade. J Immunol 2001; 167: 55225526.
  • 16
    Rulifson IC, Szot GL, Palmer E, Bluestone JA. Inability to induce tolerance through direct antigen presentation. Am J Transplant 2002; 2: 510519.
  • 17
    Lee RS, Yamada K, Houser SL et al. Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy. Proc Natl Acad Sci U S A 2001; 98: 32763281.
  • 18
    Braun MY, Grandjean I, Feunou P et al. Acute rejection in the absence of cognate recognition of allograft by T cells. J Immunol 2001; 166: 48794883.
  • 19
    Huang JF, Yang Y, Sepulveda H et al. TCR-Mediated internalization of peptide-MHC complexes acquired by T cells. Science 1999; 286: 952954.
  • 20
    Tsang JY, Chai JG, Lechler R. Antigen presentation by mouse CD4+ T cells involving acquired MHC class II. peptide complexes: another mechanism to limit clonal expansion Blood 2003; 101: 27042710.
  • 21
    Haque MA, Mizobuchi T, Yasufuku K et al. Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol 2002; 169: 15421549.
  • 22
    Yasufuku K, Heidler KM, Woods KA et al. Prevention of bronchiolitis obliterans in rat lung allografts by type V collagen-induced oral tolerance. Transplantation 2002; 73: 500505.
  • 23
    Yasufuku K, Heidler KM, O'Donnell PW et al. Oral tolerance induction by type V collagen downregulates lung allograft rejection. Am J Respir Cell Mol Biol 2001; 25: 2634.
  • 24
    Wilkes DS, Heidler KM, Yasufuku K et al. Cell-mediated immunity to collagen V in lung transplant recipients: correlation with collagen V release into BAL fluid. J Heart Lung Transplant 2001; 20: 167.
  • 25
    Mares DC, Heidler KM, Smith GN et al. Type V collagen modulates alloantigen-induced pathology and immunology in the lung. Am J Respir Cell Mol Biol 2000; 23: 6270.
  • 26
    Rolls HK, Kishimoto K, Dong VM et al. T-cell response to cardiac myosin persists in the absence of an alloimmune response in recipients with chronic cardiac allograft rejection. Transplantation 2002; 74: 10531057.
  • 27
    Fedoseyeva EV, Kishimoto K, Rolls HK et al. Modulation of tissue-specific immune response to cardiac myosin can prolong survival of allogeneic heart transplants. J Immunol 2002; 169: 11681174.
  • 28
    Rolls HK, Kishimoto K, Illigens BM et al. Detection of cardiac myosin-specific autoimmunity in a model of chronic heart allograft rejection. Transplant Proc 2001; 33: 38213822.
  • 29
    Fedoseyeva EV, Zhang F, Orr PL, Levin D, Buncke HJ, Benichou G. De novo autoimmunity to cardiac myosin after heart transplantation and its contribution to the rejection process. J Immunol 1999; 162: 68366842.
  • 30
    Valujskikh A, Fedoseyeva E, Benichou G, Heeger PS. Development of autoimmunity after skin graft rejection via an indirect alloresponse. Transplantation 2002; 73: 11301137.
  • 31
    Burlingham W, Haynes L, Janowska-Gan W et al. Correlation of bronchiolitis obliterans syndrome with autoimmunity to collagen (V) after lung transplantation [abstract]. Am J Transplant 2003; 3: 152.
  • 32
    Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002; 13: 559575.
  • 33
    Yuan X, Salama AD, Dong V et al. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J Immunol 2003; 170: 29492955.
  • 34
    Ozkaynak E, Wang L, Goodearl A et al. Programmed death-1 targeting can promote allograft survival. J Immunol 2002; 169: 65466553.
  • 35
    Lee I, Wang L, Han R et al. Targeting the MCP-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a PD-L1-dependent mechanism [abstract]. Am J Transplant 2003; 2: 551.
  • 36
    Gao W, Demirci G, Strom T, Li X. Blocking CD154 co-stimulation concurrent with stimulating PD-1 negative signals induces long-term islet allograft survival [abstract]. Am J Transplant 2003; 3: 435.
  • 37
    Salama AD, Yuan X, Nayer A et al. Interaction Between ICOS-B7RP1 and B7-CD28 Costimulatory Pathways in Alloimmune Responses In Vivo. Am J Transplant 2003; 3: 390395.
  • 38
    Guo Z, Dong Y, Wang J et al. Importance of LIGHT for alloimmune responses mediated cy CD4+ T cells [abstract]. Am J Transplant 2003; 3: 551.
  • 39
    Sprent J, Surh CD. T cell memory. Annu Rev Immunol 2002; 20: 551579.
  • 40
    Jones ND, Turvey SE, Van Maurik A et al. Differential susceptibility of heart, skin, and islet allografts to T cell-mediated rejection. J Immunol 2001; 166: 28242830.
  • 41
    Pietra BA, Wiseman A, Bolwerk A, Rizeq M, Gill RG. CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II. J Clin Invest 2000; 106: 10031010.
  • 42
    Valujskikh A, Lantz O, Celli S, Matzinger P, Heeger PS. Cross-primed CD8 (+) T cells mediate graft rejection via a distinct effector pathway. Nat Immunol 2002; 3: 844851.
  • 43
    Savinov AY, Wong FS, Stonebraker AC, Chervonsky AV. Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8 (+) T cells. J Exp Med 2003; 197: 643656.
  • 44
    Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003; 111: 15711578.
  • 45
    Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002; 8: 582587.
  • 46
    Von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol 2003; 3: 223232.
  • 47
    Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 11511164.
  • 48
    Sakaguchi S, Sakaguchi N, Shimizu J et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 1832.
  • 49
    Takahashi T, Tagami T, Yamazaki S et al. Immunologic self-tolerance maintained by CD25 (+) CD4 (+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192: 303310.
  • 50
    McHugh RS, Shevach EM. The role of suppressor T cells in regulation of immune responses. J Allergy Clin Immunol 2002; 110: 693702.
  • 51
    Shevach EM. Regulatory T cells in autoimmmunity. Annu Rev Immunol 2000; 18: 423449.
  • 52
    Wood K, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199210.
  • 53
    Bassuny WM, Ihara K, Sasaki Y et al. A functional polymorphism in the promoter/enhancer region of the FOXP3/Scurfin gene associated with type 1 diabetes. Immunogenetics 2003; 16: 16.
  • 54
    Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330336.
  • 55
    Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 10571061.
  • 56
    Wilson SB, Delovitch TL. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 2003; 3: 211222.
  • 57
    Graca L, Cobbold SP, Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002; 195: 16411646.
  • 58
    Valujskikh A, Pantenburg B, Heeger PS. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant 2002; 2: 501509.
  • 59
    Pantenburg B, Heinzel F, Das L, Heeger PS, Valujskikh A. T cells primed by Leishmania major infection cross-react with alloantigens and alter the course of allograft rejection. J Immunol 2002; 169: 36863693.
  • 60
    Brehm MA, Markees TG, Daniels KA, Greiner DL, Rossini AA, Welsh RM. Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections. J Immunol 2003; 170: 40774086.
  • 61
    Zhai Y, Meng L, Gao F, Busuttil RW, Kupiec-Weglinski JW. Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients. J Immunol 2002; 169: 46674673.
  • 62
    Kawai T, Cosimi AB, Wee SL et al. Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys. Transplantation 2002; 73: 17571764.
  • 63
    Yin D, Ma L, Varghese A, Shen J, Chong AS. Intact active bone transplantation synergizes with anti-CD40 ligand therapy to induce B cell tolerance. J Immunol 2002; 168: 53525358.
  • 64
    Xie JH, Nomura N, Koprak SL, Quackenbush EJ, Forrest MJ, Rosen H. Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4 (+) T cells. J Immunol 2003; 170: 36623670.
  • 65
    Mandala S, Hajdu R, Bergstrom J et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346349.
  • 66
    Brinkmann V, Davis MD, Heise CE et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 2145321457.
  • 67
    Grohmann U, Orabona C, Fallarino F et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 10971101.
  • 68
    Phelps CJ, Koike C, Vaught TD et al. Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003; 299: 411414.
  • 69
    Lai L, Kolber-Simonds D, Park KW et al. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 2002; 295: 10891092.
  • 70
    Auchincloss H Jr, Sachs DH. Xenogeneic transplantation. Annu Rev Immunol 1998; 16: 433470.
  • 71
    Stoll S, Delon J, Brotz TM, Germain RN. Dynamic imaging of T cell–dendritic cell interactions in lymph nodes. Science 2002; 296: 18731876.
  • 72
    Miller MJ, Wei SH, Cahalan MD, Parker I. Autonomous T cell trafficking examined in vivo with intravital two-photon microscopy. Proc Natl Acad Sci U S A 2003; 100: 26042609.
  • 73
    Koehne G, Doubrovin M, Doubrovina E et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol 2003; 21: 405413.